C-MET 및 HGF 저해제 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

The global market for C-MET & HGF Inhibitors was estimated to be worth US$ 3480 million in 2024 and is forecast to a readjusted size of US$ 10713 million by 2031 with a CAGR of 17.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on C-MET & HGF Inhibitors cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

C-MET & HGF inhibitors are a class of targeted therapies designed to inhibit the aberrant activation of the hepatocyte growth factor (HGF) and its receptor c-MET signaling pathway. This axis is implicated in tumorigenesis processes such as proliferation, invasion, angiogenesis, and metastasis, especially in cancers such as hepatocellular carcinoma, lung cancer, gastric cancer, and renal cancer. The inhibitors include small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. In recent years, they have become a key focus in oncology drug development. Drugs such as Capmatinib and Tepotinib, approved by the FDA, are accelerating market expansion with demonstrated clinical efficacy and safety. In 2024, global C-MET & HGF Inhibitors production reached approximately 24 million unit, with an average global market price of around US$ 145/unit.

The abnormal activation or overexpression of the c-MET/HGF signaling pathway in multiple malignancies provides a clear target for precision oncology. As revealed in annual reports from Pfizer and Novartis, several approved C-MET inhibitors have achieved rapid commercialization, especially in late-stage NSCLC. With the expanding global oncology market and increasing adoption of individualized treatment protocols, C-MET & HGF inhibitors possess significant potential for indication expansion. The growing availability of molecular diagnostics, such as RNA sequencing, further accelerates the identification of C-MET-positive patients, boosting treatment penetration.

Despite promising clinical outcomes, C-MET & HGF inhibitors face challenges including inconsistent efficacy, complex resistance mechanisms, and adverse event management. Some early candidates have underperformed in Phase III trials or faced setbacks due to the lack of standardized biomarker-based patient selection. Regulatory pressures are mounting worldwide, demanding robust real-world evidence for safety and efficacy, thus increasing development timelines and costs.

There is growing clinical acceptance of precision-targeted therapies, integrating C-MET inhibitors into multi-line treatment regimens. According to IQVIA and FDA data, numerous global clinical trials are exploring combination therapies involving C-MET inhibitors and immune checkpoint inhibitors. In China, Korea, and other markets, reimbursement policy improvements and the rise of local biotech players are expected to significantly accelerate market penetration in the coming years.

This report aims to provide a comprehensive presentation of the global market for C-MET & HGF Inhibitors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of C-MET & HGF Inhibitors by region & country, by Type, and by Application.

The C-MET & HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET & HGF Inhibitors.

Market Segmentation

By Company

• Exelixis
• Ipsen
• Pfizer
• Novartis
• Takeda
• Merck KGaA
• Takeda Pharmaceutical

Segment by Type

• Cabozantinib
• Crizotinib
• Tepotinib
• Others

Segment by Application

• Hospital
• Drug Store

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of C-MET & HGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of C-MET & HGF Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 C-MET & HGF Inhibitors Product Introduction
• 1.2 Global C-MET & HGF Inhibitors Market Size Forecast
  • 1.2.1 Global C-MET & HGF Inhibitors Sales Value (2020-2031)
  • 1.2.2 Global C-MET & HGF Inhibitors Sales Volume (2020-2031)
  • 1.2.3 Global C-MET & HGF Inhibitors Sales Price (2020-2031)
• 1.3 C-MET & HGF Inhibitors Market Trends & Drivers
  • 1.3.1 C-MET & HGF Inhibitors Industry Trends
  • 1.3.2 C-MET & HGF Inhibitors Market Drivers & Opportunity
  • 1.3.3 C-MET & HGF Inhibitors Market Challenges
  • 1.3.4 C-MET & HGF Inhibitors Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global C-MET & HGF Inhibitors Players Revenue Ranking (2024)
• 2.2 Global C-MET & HGF Inhibitors Revenue by Company (2020-2025)
• 2.3 Global C-MET & HGF Inhibitors Players Sales Volume Ranking (2024)
• 2.4 Global C-MET & HGF Inhibitors Sales Volume by Company Players (2020-2025)
• 2.5 Global C-MET & HGF Inhibitors Average Price by Company (2020-2025)
• 2.6 Key Manufacturers C-MET & HGF Inhibitors Manufacturing Base and Headquarters
• 2.7 Key Manufacturers C-MET & HGF Inhibitors Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of C-MET & HGF Inhibitors
• 2.9 C-MET & HGF Inhibitors Market Competitive Analysis
  • 2.9.1 C-MET & HGF Inhibitors Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by C-MET & HGF Inhibitors Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Cabozantinib
  • 3.1.2 Crizotinib
  • 3.1.3 Tepotinib
  • 3.1.4 Others
• 3.2 Global C-MET & HGF Inhibitors Sales Value by Type
  • 3.2.1 Global C-MET & HGF Inhibitors Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global C-MET & HGF Inhibitors Sales Value, by Type (2020-2031)
  • 3.2.3 Global C-MET & HGF Inhibitors Sales Value, by Type (%) (2020-2031)
• 3.3 Global C-MET & HGF Inhibitors Sales Volume by Type
  • 3.3.1 Global C-MET & HGF Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global C-MET & HGF Inhibitors Sales Volume, by Type (2020-2031)
  • 3.3.3 Global C-MET & HGF Inhibitors Sales Volume, by Type (%) (2020-2031)
• 3.4 Global C-MET & HGF Inhibitors Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hospital
  • 4.1.2 Drug Store
• 4.2 Global C-MET & HGF Inhibitors Sales Value by Application
  • 4.2.1 Global C-MET & HGF Inhibitors Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global C-MET & HGF Inhibitors Sales Value, by Application (2020-2031)
  • 4.2.3 Global C-MET & HGF Inhibitors Sales Value, by Application (%) (2020-2031)
• 4.3 Global C-MET & HGF Inhibitors Sales Volume by Application
  • 4.3.1 Global C-MET & HGF Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global C-MET & HGF Inhibitors Sales Volume, by Application (2020-2031)
  • 4.3.3 Global C-MET & HGF Inhibitors Sales Volume, by Application (%) (2020-2031)
• 4.4 Global C-MET & HGF Inhibitors Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global C-MET & HGF Inhibitors Sales Value by Region
  • 5.1.1 Global C-MET & HGF Inhibitors Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global C-MET & HGF Inhibitors Sales Value by Region (2020-2025)
  • 5.1.3 Global C-MET & HGF Inhibitors Sales Value by Region (2026-2031)
  • 5.1.4 Global C-MET & HGF Inhibitors Sales Value by Region (%), (2020-2031)
• 5.2 Global C-MET & HGF Inhibitors Sales Volume by Region
  • 5.2.1 Global C-MET & HGF Inhibitors Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global C-MET & HGF Inhibitors Sales Volume by Region (2020-2025)
  • 5.2.3 Global C-MET & HGF Inhibitors Sales Volume by Region (2026-2031)
  • 5.2.4 Global C-MET & HGF Inhibitors Sales Volume by Region (%), (2020-2031)
• 5.3 Global C-MET & HGF Inhibitors Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.4.2 North America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.5.2 Europe C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.6.2 Asia Pacific C-MET & HGF Inhibitors Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.7.2 South America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions C-MET & HGF Inhibitors Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions C-MET & HGF Inhibitors Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions C-MET & HGF Inhibitors Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.3.2 United States C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.4.2 Europe C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.5.2 China C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.6.2 Japan C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.7.2 South Korea C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.8.2 Southeast Asia C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.9.2 India C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Exelixis
  • 7.1.1 Exelixis Company Information
  • 7.1.2 Exelixis Introduction and Business Overview
  • 7.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Exelixis C-MET & HGF Inhibitors Product Offerings
  • 7.1.5 Exelixis Recent Development
• 7.2 Ipsen
  • 7.2.1 Ipsen Company Information
  • 7.2.2 Ipsen Introduction and Business Overview
  • 7.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Ipsen C-MET & HGF Inhibitors Product Offerings
  • 7.2.5 Ipsen Recent Development
• 7.3 Pfizer
  • 7.3.1 Pfizer Company Information
  • 7.3.2 Pfizer Introduction and Business Overview
  • 7.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Pfizer C-MET & HGF Inhibitors Product Offerings
  • 7.3.5 Pfizer Recent Development
• 7.4 Novartis
  • 7.4.1 Novartis Company Information
  • 7.4.2 Novartis Introduction and Business Overview
  • 7.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Novartis C-MET & HGF Inhibitors Product Offerings
  • 7.4.5 Novartis Recent Development
• 7.5 Takeda
  • 7.5.1 Takeda Company Information
  • 7.5.2 Takeda Introduction and Business Overview
  • 7.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Takeda C-MET & HGF Inhibitors Product Offerings
  • 7.5.5 Takeda Recent Development
• 7.6 Merck KGaA
  • 7.6.1 Merck KGaA Company Information
  • 7.6.2 Merck KGaA Introduction and Business Overview
  • 7.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Merck KGaA C-MET & HGF Inhibitors Product Offerings
  • 7.6.5 Merck KGaA Recent Development
• 7.7 Takeda Pharmaceutical
  • 7.7.1 Takeda Pharmaceutical Company Information
  • 7.7.2 Takeda Pharmaceutical Introduction and Business Overview
  • 7.7.3 Takeda Pharmaceutical C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Takeda Pharmaceutical C-MET & HGF Inhibitors Product Offerings
  • 7.7.5 Takeda Pharmaceutical Recent Development

8 Industry Chain Analysis

• 8.1 C-MET & HGF Inhibitors Industrial Chain
• 8.2 C-MET & HGF Inhibitors Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 C-MET & HGF Inhibitors Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 C-MET & HGF Inhibitors Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer